EP Patent

EP2796139A1 — Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias

Assigned to AOP Orphan Pharmaceuticals AG · Expires 2014-10-29 · 12y expired

What this patent protects

The invention provides a new use of landiolol hydrochloride in the treatment of a subject suffering from tachycardia or tachyarrhythmia, wherein landiolol-hydrochloride is administered for a period of at least 0.5 hours and up to at least 2 days, wherein the heart rate of said pa…

USPTO Abstract

The invention provides a new use of landiolol hydrochloride in the treatment of a subject suffering from tachycardia or tachyarrhythmia, wherein landiolol-hydrochloride is administered for a period of at least 0.5 hours and up to at least 2 days, wherein the heart rate of said patient is persistently reduced during the administration period compared to the heart rate before treatment and no overshooting effect occurs after termination of said administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2796139A1
Jurisdiction
EP
Classification
—
Expires
2014-10-29
Drug substance claim
No
Drug product claim
No
Assignee
AOP Orphan Pharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.